---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-24-000037"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T07:24:58.790340+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Edwards Q1 sales $1.6B (+10%), TMTT +75%; raises FY sales guidance to high end 8-10%

## Summary
- Q1 sales $1.6B, up 10% reported and constant currency; GAAP EPS $0.58, adjusted EPS $0.66.
- TAVR sales $1.0B (+6% reported, +8% constant currency adjusted for billing days).
- TMTT sales $73M (+75%); EVOQUE received FDA approval for tricuspid regurgitation in Feb.
- Full-year 2024 sales guidance raised to high end of 8-10% range; TMTT guidance raised to $320-340M.
- Critical Care spin-off on track; full-year adjusted EPS guidance maintained at $2.70-$2.80.

## SEC filing metadata
- accession: 0001099800-24-000037
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980024000037/0001099800-24-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980024000037/ew-20240425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-24-000037
- JSON: https://secwatch.observer/filing/0001099800-24-000037.json
- Plain text: https://secwatch.observer/filing/0001099800-24-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.